| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2016 | 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs | BIN-CHI LIAO ; Bai Y.-Y.; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 1 | 1 | |
| 2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 74 | 64 | |
| 2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
| 2019 | ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer | Shaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F. | Journal of Clinical Oncology | 234 | 191 | |
| 2016 | Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort | Chow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y. | Journal of Clinical Oncology | 606 | 121 | |
| 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 101 | 100 | |
| 2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 27 | 25 | |
| 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 40 | 38 | |
| 2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Feng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG | Annals of Surgical Oncology | 33 | 32 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 13 | 13 | |
| 2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
| 2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 16 | 17 | |
| 2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 83 | 78 | |
| 2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | CHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. | Targeted Oncology | 14 | 10 | |
| 2021 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial | Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; CHIA-CHI LIN ; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. | The Lancet Oncology | 83 | 76 | |
| 2013 | Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial | Smith D.C.; Smith M.R.; Sweeney C.; Elfiky A.A.; Logothetis C.; Corn P.G.; Vogelzang N.J.; Small E.J.; Harzstark A.L.; Gordon M.S.; Vaishampayan U.N.; Haas N.B.; Spira A.I.; Lara Jr. P.N.; CHIA-CHI LIN ; Srinivas S.; Sella A.; Sch?ffski P.; Scheffold C.; Weitzman A.L.; Hussain M. | Journal of Clinical Oncology | 366 | 341 | |
| 2013 | Case report | CHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU | Journal of Clinical Oncology | 6 | 7 | |
| 2019 | Challenges of the phase I drug development in non-small cell lung cancer | CHIA-CHI LIN | Chinese Clinical Oncology | 4 | 8 | |
| 2004 | Changing trends of prostate cancer in Asia | YEONG-SHIAU PU ; Chiang H.-S.; CHIA-CHI LIN ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J. | Aging Male | 102 | 0 | |
| 2004 | Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide | Hour T.-C.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Chen J.; Guan J.-Y.; Lee J.-M.; YEONG-SHIAU PU | Anti-Cancer Drugs | 24 | 23 | |
